New anticoagulant gets mixed results
Idraparinux is a new anticoagulant that inhibits activated factor X. It has a long half life and can be given just once a week, by subcutaneous injection. But is it as good as standard anticoagulants at preventing recurrent venous thromboembolism?
In two parallel trials, the new drug worked well for patients with deep vein thrombosis but not so well for those with a pulmonary embolus.
Both trials compared idraparinux with the usual regimen of intravenous heparin followed by warfarin for three to six months. Among 2904 patients with deep vein thrombosis, risk of a recurrence was about the same in both groups (odds ratio 0.98 for idraparinux, 95% CI 0.63 to 1.50 at three months), but idraparinux caused fewer clinically relevant bleeding complications. Among 2215 patients with pulmonary embolus, idraparinux was associated with a significantly higher rate of recurrence at both three and six months (2.14; 1.21 to 3.78 at three months). It was also associated with a significant excess of deaths (6.4% v 4.4% at six months, P=0.04), including deaths from pulmonary embolus.
Bleeding was less of a problem for patients taking idraparinux in both trials. But the authors warn that the new agent has a very long half life, and there's no antidote when bleeding does occur. Dabigatran as good as enoxaparin for thromboembolic prophylaxis after hip replacement Dabigatran etexilate is another new anticoagulant, an oral inhibitor of thrombin that could help prevent venous thromboembolism after major orthopaedic surgery. The manufacturers tested it in a head to head trial against subcutaneous enoxaparin. They found that after about a month of treatment, the two drugs worked equally well in patients having a hip replacement. Rates of deep vein thrombosis, pulmonary embolism, or death were similar in all three randomised groups-6.7% (60/897) for patients given enoxaparin, 6.0% (53/880) for those given a high dose of dabigatran, and 8.6% (75/874) for those given a lower dose.
No extra bleeding complications occurred in patients given the new agent in either dose. But there were too few events to be completely certain about this result. Bigger trials focusing on safety are now needed, say the authors.
The trial's biggest limitation was that nearly a quarter of the patients were excluded from the analysis, mostly because they didn't have a venogram or the image wasn't clear enough to interpret. This is a common problem for researchers using venography to look for venous thromboembolism, says an editorial (p 915). Its effects are unknown. Lancet 2007; 370:949-56 
Meta-analysis confirms rosiglitazone's poor safety record
Rosiglitazone is still approved by the US Food and Drugs Administration (FDA) for the treatment of type 2 diabetes, despite evidence from meta-analyses that it is associated with an increased risk of heart attack and heart failure.
A third meta-analysis, this time confined to four trials lasting more than a year, confirms these earlier findings. Patients taking rosiglitazone were 42% more likely to have a heart attack than controls taking other oral hypoglycaemic agents or placebo (94/6421 v 83/7870; relative risk, 1.42, 95% CI 1.06 to 1.91). They were also twice as likely to develop heart failure (2.09, 1.52 to 2.88), a well known side effect of drugs in this class. Rosiglitazone was not associated with any excess deaths. The authors and a linked editorial (p 1216) agree that regulatory agencies will need to look again at this agent. In the meantime doctors should think carefully before prescribing it.
Pioglitazone, another drug from the same family, seems to have a strikingly different effect on ischaemic events. In a meta-analysis of 19 randomised trials, pioglitazone reduced the chance of a heart attack, stroke, or death by 18% (hazard ratio 0.82, 0.72 to 0.94). As expected, heart failure remained a problem. The FDA has issued black box warnings about the risk of heart failure with both drugs. 
Diesel pollution promotes myocardial ischaemia
Air pollution is associated with an increased risk of cardiovascular events such as heart attack, arrythmias, and even death. To investigate why, researchers from Europe did a controlled experiment on 20 men with stable coronary heart disease. The men exercised on a bicycle ergometer in clean air and in air containing diesel fumes at a concentration found in heavy traffic. As expected, the men had asymptomatic myocardial ischaemia during the exercise periods. But it was significantly worse when they were exposed to diesel. Six hours later, blood tests also showed a significant association between exercising in polluted air and impaired fibrinolysis. The researchers found no evidence of an effect on peripheral vasodilation. They used an idling Volvo to generate diesel pollution containing 300 µg/m 3 of particulate matter, the component most consistently implicated in cardiovascular events. It now seems likely that these particles have proischaemic effects, which could help explain why even short term exposure to pollution has been linked to heart attack. An editorial (p 1147) says people should exercise away from heavy traffic if possible. disease. It didn't work. Children given the drug in addition to their other drugs for heart failure were just as likely to get worse as children given a placebo (25/103 (24%) v 16/54 (30%); odds ratio 0.79, 95% CI 0.36 to 1.59).
The result was surprising-because β blockers work so well in adults-and disappointing. It is possible that the trial was too small to find a clinically relevant difference between the groups, say the authors. Or perhaps the outcome they used wasn't sensitive enough, the dose of carvedilol wasn't big enough, or the children were too heterogeneous.
Alternatively, β blockers may work differently on young hearts that fail from aetiologies other than ischaemia. Children are not simply small adults, says an editorial (p 1214). This trial is an important illustration of the limitations of using adult evidence in children. JAMA 2007; 298:1171-9 supplements to lower homocysteine concentration disappoint again Epidemiological and genetic studies show a clear association between high serum concentrations of homocysteine and a higher risk of cardiovascular disease. So for more than a decade, researchers have been trying to reduce the risk of cardiovascular disease by giving people homocysteine lowering supplements of B vitamins and folic acid. Four large trials have already reported disappointing results. Now a fifth finds that B vitamins and folic acid don't prevent cardiovascular disease, even in high risk patients with chronic renal failure. Once again, the supplements brought down participant's homocysteine concentrations but not their risk of death (hazard ratio 1.04, 95% CI 0.91 to 1.18), heart attack (0.86, 0.67 to 1.08), stroke (0.90, 0.58 to 1.40), or amputation (1.14, 0.79 to 1.64).
No one can explain why the supplements don't work in large trials, although one explanation is the attenuating effect of fortifying cereals with folic acid. Most of the trials have been done in the US, where fortification is compulsory. Further trials are still under way and when finished will bring the total number of analysable participants to about 52 000. That should be enough to detect even a small effect, says an editorial (p 1212). Unless, of course, there isn't one. JAMA 2007; 298:1163-70 latest round in the stent controversy favours sirolimus eluting stents
In response to ongoing controversy about the safety of drug eluting stents compared with bare metal stents, researchers analysed data from 38 randomised trials including more than 18 000 people with coronary ischaemia. Bare metal stents, paclitaxel eluting stents, and sirolimus eluting stents were all associated with similar overall mortality and similar cardiac mortality over four years. But patients given a sirolimus eluting stent were significantly less likely to have a heart attack than patients given the other two types of stent. Both drug eluting stents reduced the need for further revascularisation compared with bare metal stents. The difference was greatest for stents eluting sirolimus (hazard ratio 0.7, 95% credibility interval 0.56 to 0.84).
All three stent types were associated with similar rates of stent thrombosis overall. Patients with paclitaxel eluting stents had around twice as many late thromboses (after more than 30 days) than patients with either bare metal or sirolimus eluting stents.
These findings are the most precise so far, and they suggest that sirolimus eluting stents have a better risk-benefit ratio than the only other drug eluting stent on the market. This meta-analysis was designed, analysed, interpreted, and published independently of sponsors. Lancet 2007; 370:937-48 Vaccines against typhoid fever deserve a higher priority Typhoid fever still kills more than half a million people every year worldwide and causes serious illness in many more. But it remains a low profile disease, largely ignored by the international health community, say commentators from the International Vaccine Institute in Korea. Recent studies have documented high incidences of typhoid fever in children living in urban slums in Indonesia, Pakistan, and Vietnam. Cheap antibiotics such as ampicillin that used to control the infection are becoming increasingly ineffective because of resistance, 
